More Eye Exams In Stand-Alone Plans


A new study reveals that consumers who participate in full-service, stand-alone vision insurance plans are two times as likely to have an annual comprehensive eye examination as consumers that have vision care coverage through their major medical plan (33 percent versus 16 percent). The study, conducted for the National Association of Vision Care Plans (NAVCP), reviewed eye exam patterns of nearly 85 million Americans during 2008 and 2009.

The high number of eye exams is important — a comprehensive eye examination can detect early signs of some chronic diseases.

Richard Sanchez, president and CEO of Advantica Eyecare, a vision benefit company, and current president of NAVCP, says, “People use their benefit and, importantly, they’re finding value in their benefit.” But why is there more utilization in stand-alone plans than in bundled plans?

“A medical plan isn’t doing anything wrong. The networks in a bundled plan are comparable to the stand-alone plan. But there’s probably more awareness of the benefit on the part of the member in stand-alone vision plans — it’s more single-focused,” says Sanchez.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.